Kibra knockdown inhibits the aberrant Hippo pathway, suppresses renal cyst formation and ameliorates renal fibrosis in nphp1KO mice

IF 6.8 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Clinical and Translational Medicine Pub Date : 2025-02-24 DOI:10.1002/ctm2.70245
Yichen Yang, Zhihe Xue, Jiayong Lai, Jinglan Zhang, Changmiao Pang, Jinglin Zhong, Zhanpeng Kuang, Baojuan Zou, Yaqing Liu, Liangzhong Sun
{"title":"Kibra knockdown inhibits the aberrant Hippo pathway, suppresses renal cyst formation and ameliorates renal fibrosis in nphp1KO mice","authors":"Yichen Yang,&nbsp;Zhihe Xue,&nbsp;Jiayong Lai,&nbsp;Jinglan Zhang,&nbsp;Changmiao Pang,&nbsp;Jinglin Zhong,&nbsp;Zhanpeng Kuang,&nbsp;Baojuan Zou,&nbsp;Yaqing Liu,&nbsp;Liangzhong Sun","doi":"10.1002/ctm2.70245","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Nephronophthisis (NPH) is an autosomal recessive interstitial cystic kidney disease, which is the most common genetic cause of end-stage renal disease (ESRD) in childhood. The Hippo pathway is regulated by the cilium and has been suggested to be linked to NPH. The aim of the study was to investigate the involvement of Hippo pathway in the pathogenesis of <i>nphp1</i> defect-associated NPH (NPH1).</p>\n </section>\n \n <section>\n \n <h3> Method</h3>\n \n <p><i>Nphp1</i> knockout (<i>nphp1</i><sup>KO</sup>) Madin-Darby Canine Kidney (MDCK) cells and <i>nphp1</i><sup>KO</sup> C57BL/6J mice were generated via CRISPR gene editing strategy. The siRNAs targeting <i>Kibra</i>, <i>MST1</i> and <i>LATS1</i> were designed. An AAV9 vector was designed for <i>Kibra</i> knockdown. The expression and phosphorylation of core Hippo pathway molecules were evaluated. Pathological renal changes were evaluated via light microscopy respectively with haematoxylin–eosin and Masson staining.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In <i>nphp1</i><sup>KO</sup> MDCK cells, <i>nphp1</i><sup>KO</sup> mice and NPH1 patients’ kidneys, Kibra, p-MST1/2, p-LATS and p-YAP exhibited a notable increase in levels, with an even greater elevation observed in renal cyst cells, indicating the Hippo pathway activated in these <i>nphp1</i>-deficient contexts. <i>Nphp1</i> re-expression reversed the Hippo pathway activation in cells, indicating that the Hippo pathway activation is related to <i>nphp1</i> deficiency in vitro. Meanwhile, in vitro, <i>MST1</i> knockdown downregulated LATS1 and YAP phosphorylation, <i>LATS1</i> knockdown downregulated YAP phosphorylation, suggesting the activation of the canonical Hippo pathway in <i>nphp1</i>-deficient contexts. Knockdown of the upstream regulator <i>Kibra</i> inhibited the Hippo pathway activation in both <i>nphp1</i><sup>KO</sup> MDCK cells and mice. Following <i>Kibra</i> knockdown, the organisation of <i>nphp1</i><sup>KO</sup> MDCK cells became more compact, the intensity of the actin fibres increased. Besides, decreased renal fibrosis and cyst formation were observed in <i>nphp1</i><sup>KO</sup> mice.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The canonical Hippo pathway is aberrantly activated in <i>nphp1</i>-deficient conditions. <i>Kibra</i> may serve as a crucial upstream regulator of <i>nphp1</i> deficiency-related Hippo pathway activation. <i>Kibra</i> upregulation and activation of the Hippo pathway are involved in the pathogenesis of NPH1.</p>\n </section>\n \n <section>\n \n <h3> Key Points</h3>\n \n <div>\n <ul>\n \n <li>Canonical Hippo pathway activated in <i>nphp1</i>-deficient disease models and patients.</li>\n \n <li>Kibra was a key upstream molecule in regulating the activation of canonical Hippo pathway in <i>nphp1</i>-deficient disease models and patients and closely related to renal cyst formation and fibrosis in <i>nphp1</i><sup>KO</sup> mice.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"15 3","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctm2.70245","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ctm2.70245","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Nephronophthisis (NPH) is an autosomal recessive interstitial cystic kidney disease, which is the most common genetic cause of end-stage renal disease (ESRD) in childhood. The Hippo pathway is regulated by the cilium and has been suggested to be linked to NPH. The aim of the study was to investigate the involvement of Hippo pathway in the pathogenesis of nphp1 defect-associated NPH (NPH1).

Method

Nphp1 knockout (nphp1KO) Madin-Darby Canine Kidney (MDCK) cells and nphp1KO C57BL/6J mice were generated via CRISPR gene editing strategy. The siRNAs targeting Kibra, MST1 and LATS1 were designed. An AAV9 vector was designed for Kibra knockdown. The expression and phosphorylation of core Hippo pathway molecules were evaluated. Pathological renal changes were evaluated via light microscopy respectively with haematoxylin–eosin and Masson staining.

Results

In nphp1KO MDCK cells, nphp1KO mice and NPH1 patients’ kidneys, Kibra, p-MST1/2, p-LATS and p-YAP exhibited a notable increase in levels, with an even greater elevation observed in renal cyst cells, indicating the Hippo pathway activated in these nphp1-deficient contexts. Nphp1 re-expression reversed the Hippo pathway activation in cells, indicating that the Hippo pathway activation is related to nphp1 deficiency in vitro. Meanwhile, in vitro, MST1 knockdown downregulated LATS1 and YAP phosphorylation, LATS1 knockdown downregulated YAP phosphorylation, suggesting the activation of the canonical Hippo pathway in nphp1-deficient contexts. Knockdown of the upstream regulator Kibra inhibited the Hippo pathway activation in both nphp1KO MDCK cells and mice. Following Kibra knockdown, the organisation of nphp1KO MDCK cells became more compact, the intensity of the actin fibres increased. Besides, decreased renal fibrosis and cyst formation were observed in nphp1KO mice.

Conclusions

The canonical Hippo pathway is aberrantly activated in nphp1-deficient conditions. Kibra may serve as a crucial upstream regulator of nphp1 deficiency-related Hippo pathway activation. Kibra upregulation and activation of the Hippo pathway are involved in the pathogenesis of NPH1.

Key Points

  • Canonical Hippo pathway activated in nphp1-deficient disease models and patients.
  • Kibra was a key upstream molecule in regulating the activation of canonical Hippo pathway in nphp1-deficient disease models and patients and closely related to renal cyst formation and fibrosis in nphp1KO mice.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Kibra敲低抑制异常Hippo通路,抑制肾囊肿形成,改善nphp1KO小鼠肾纤维化
肾病(nephronophthis, NPH)是一种常染色体隐性间质性囊性肾病,是儿童期终末期肾病(ESRD)最常见的遗传原因。Hippo通路受纤毛调控,并被认为与NPH有关。本研究的目的是探讨Hippo通路在nphp1缺陷相关NPH (NPH1)发病机制中的作用。方法采用CRISPR基因编辑策略制备Nphp1敲除(nphp1KO) Madin-Darby犬肾(MDCK)细胞和nphp1KO C57BL/6J小鼠。设计了靶向Kibra、MST1和LATS1的sirna。设计了一种AAV9载体来敲除Kibra。评估Hippo通路核心分子的表达和磷酸化情况。光镜下分别用红木精-伊红染色和马松染色评价肾脏病理改变。结果在nphp1KO MDCK细胞中,nphp1KO小鼠和NPH1患者的肾脏、Kibra、p-MST1/2、p-LATS和p-YAP水平显著升高,在肾囊肿细胞中观察到的升高幅度更大,表明Hippo通路在这些nphp1缺乏的情况下被激活。在细胞中,Nphp1的重新表达逆转了Hippo通路的激活,表明Hippo通路的激活与体外Nphp1缺乏有关。同时,在体外,MST1敲低可下调LATS1和YAP的磷酸化,LATS1敲低可下调YAP的磷酸化,提示在nphp1缺失的情况下,典型的Hippo通路被激活。在nphp1KO MDCK细胞和小鼠中,上游调节因子Kibra的敲低抑制Hippo通路的激活。Kibra基因敲除后,nphp1KO MDCK细胞的组织结构变得更加紧密,肌动蛋白纤维的强度增加。此外,nphp1KO小鼠肾脏纤维化和囊肿形成减少。结论在nphp1缺乏的情况下,典型的Hippo通路异常激活。Kibra可能是nphp1缺陷相关的Hippo通路激活的重要上游调节因子。Kibra的上调和Hippo通路的激活参与了NPH1的发病机制。典型Hippo通路在nphp1缺陷疾病模型和患者中激活。Kibra是nphp1缺陷疾病模型和患者中调控典型Hippo通路激活的关键上游分子,与nphp1KO小鼠肾囊肿形成和纤维化密切相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
文献相关原料
公司名称
产品信息
索莱宝
phosphatase inhibitor
来源期刊
CiteScore
15.90
自引率
1.90%
发文量
450
审稿时长
4 weeks
期刊介绍: Clinical and Translational Medicine (CTM) is an international, peer-reviewed, open-access journal dedicated to accelerating the translation of preclinical research into clinical applications and fostering communication between basic and clinical scientists. It highlights the clinical potential and application of various fields including biotechnologies, biomaterials, bioengineering, biomarkers, molecular medicine, omics science, bioinformatics, immunology, molecular imaging, drug discovery, regulation, and health policy. With a focus on the bench-to-bedside approach, CTM prioritizes studies and clinical observations that generate hypotheses relevant to patients and diseases, guiding investigations in cellular and molecular medicine. The journal encourages submissions from clinicians, researchers, policymakers, and industry professionals.
期刊最新文献
P2X7R deficiency alleviates cardiac senescence by enhancing mitophagy via the HuR/TRIM26/NR4A1 axis. Revolutionising acute aortic syndrome diagnosis: The role of artificial intelligence in non-contrast computed tomography Two pathogens, one disease: Rethinking leprosy diversification through ancient and modern genomes The insider's perspective: The intracellular complosome and immune cell dynamics in cancer Lactylation in colorectal cancer: Unveiling novel mechanisms in metabolism, progression and therapeutic targeting
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1